Bach Xuan Tran1. 1. Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Viet Nam. bach@hmu.edu.vn
Abstract
OBJECTIVE: Willingness to pay for methadone maintenance treatment (MMT) in three Vietnamese epicentres of injection-drug-driven human immunodeficiency virus (HIV) infection was assessed. METHODS: A convenience sample of 1016 patients receiving HIV treatment in seven clinics was enrolled during 2012. Contingent valuation was used to assess willingness to pay. Interviewers reviewed adverse consequences of injection drug use and the benefits of MMT. Interviewers then described the government's plan to scale up MMT and the financial barriers to scale-up. Willingness to pay was assessed using double-bounded binary questions and a follow-up open-ended question. Point and interval data models were used to estimate maximum willingness to pay. FINDINGS: A total of 548 non-drug-users and 468 injection drug users were enrolled; 988 were willing to pay for MMT. Monthly mean willingness to pay among non-drug-users, 347 drug users not receiving MMT and 121 drug users receiving MMT was 10.7 United States dollars [US$] (35.7% of treatment costs), US$ 21.1 (70.3%) and US$ 26.2 (87.3%), respectively (mean: US$ 15.9; 95% confidence interval, CI: 13.6-18.1). Fifty per cent of drug users were willing to pay 50% of MMT costs. Residence in households with low monthly per capita income and poor health status predicted willingness to pay less among drug users; educational level, employment status, health status and current antiretroviral therapy receipt predicted willingness to pay less among non-drug-users. CONCLUSION: Willingness to pay for MMT was very high, supporting implementation of a co-payment programme.
OBJECTIVE: Willingness to pay for methadone maintenance treatment (MMT) in three Vietnamese epicentres of injection-drug-driven human immunodeficiency virus (HIV) infection was assessed. METHODS: A convenience sample of 1016 patients receiving HIV treatment in seven clinics was enrolled during 2012. Contingent valuation was used to assess willingness to pay. Interviewers reviewed adverse consequences of injection drug use and the benefits of MMT. Interviewers then described the government's plan to scale up MMT and the financial barriers to scale-up. Willingness to pay was assessed using double-bounded binary questions and a follow-up open-ended question. Point and interval data models were used to estimate maximum willingness to pay. FINDINGS: A total of 548 non-drug-users and 468 injection drug users were enrolled; 988 were willing to pay for MMT. Monthly mean willingness to pay among non-drug-users, 347 drug users not receiving MMT and 121 drug users receiving MMT was 10.7 United States dollars [US$] (35.7% of treatment costs), US$ 21.1 (70.3%) and US$ 26.2 (87.3%), respectively (mean: US$ 15.9; 95% confidence interval, CI: 13.6-18.1). Fifty per cent of drug users were willing to pay 50% of MMT costs. Residence in households with low monthly per capita income and poor health status predicted willingness to pay less among drug users; educational level, employment status, health status and current antiretroviral therapy receipt predicted willingness to pay less among non-drug-users. CONCLUSION: Willingness to pay for MMT was very high, supporting implementation of a co-payment programme.
Authors: Robert Hecht; John Stover; Lori Bollinger; Farzana Muhib; Kelsey Case; David de Ferranti Journal: Lancet Date: 2010-10-09 Impact factor: 79.321
Authors: D Bishai; J Sindelar; E P Ricketts; S Huettner; L Cornelius; J J Lloyd; J R Havens; C A Latkin; S A Strathdee Journal: J Health Econ Date: 2007-12-05 Impact factor: 3.883
Authors: Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Nhan Thi Do; Long Thanh Nguyen; Quoc Cuong Nguyen; Steve Mills; Philip Jacobs; Stan Houston Journal: Qual Life Res Date: 2011-07-06 Impact factor: 4.147
Authors: Bach Xuan Tran; Arto Ohinmaa; Long Thanh Nguyen; Pauline Oosterhoff; Phu Xuan Vu; Tam Van Vu; Mattias Larsson Journal: AIDS Care Date: 2012-03-01
Authors: Bach Xuan Tran; Arto Ohinmaa; Steve Mills; Anh Thuy Duong; Long Thanh Nguyen; Philip Jacobs; Stan Houston Journal: PLoS One Date: 2012-12-12 Impact factor: 3.240
Authors: Thu Trang Nguyen; Anh Ngoc Luong; Thi Tuyet Thanh Nham; Carole Chauvin; Jonathan Feelemyer; Nicolas Nagot; Don Des Jarlais; Minh Giang Le; Marie Jauffret-Roustide Journal: Int J Drug Policy Date: 2019-04-09
Authors: David C Perlman; Ashly E Jordan; Anneli Uuskula; Duong Thi Huong; Carmen L Masson; Bruce R Schackman; Don C Des Jarlais Journal: Int J Drug Policy Date: 2015-04-27
Authors: Nhung Phuong Thi Nguyen; Bach Xuan Tran; Lu Y Hwang; Christine M Markham; Michael D Swartz; Huong Thu Thi Phan; Vuong Minh Nong; Cuong Tat Nguyen; Anh Hue Nguyen; Carl A Latkin; Damon J Vidrine Journal: PLoS One Date: 2015-02-27 Impact factor: 3.240
Authors: Bach Xuan Tran; Long Hoang Nguyen; Lan Phuong Nguyen; Cuong Tat Nguyen; Huong Thi Thu Phan; Carl A Latkin Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240